Antigen-binding molecule containing two antigen-binding domains that are linked to each other

Patent metadata

Field	Value
Publication number	US-2022195045-A1
Application number	US-201917264388-A
Country	US
Kind code	A1
Filing date	Aug 2, 2019
Priority date	Aug 3, 2018
Publication date	Jun 23, 2022
Grant date	—

Abstract

In a non-limiting embodiment, the present invention relates to antigen-binding molecules comprising two or more antigen-binding domains which are linked with each other. In a non-limiting embodiment, the antigen-binding molecules of the present disclosure have activity of holding two or more antigen molecules at spatially close positions, activity of regulating interaction between two or more antigen molecules, activity of regulating activation of two or more antigen molecules which are activated by association with each other, resistance to protease cleavage, or such.

First claim

1 . An antigen-binding molecule comprising a first antigen-binding domain and a second antigen-binding domain, wherein the two antigen-binding domains are linked with each other via one or more bonds.

2 . The antigen-binding molecule of claim 1 , wherein at least one of the bonds linking the two antigen-binding domains is a covalent bond.

3 . The antigen-binding molecule of claim 1 , wherein at least one of the first and second antigen-binding domains comprises an antibody fragment which binds to a particular antigen.

4 . The antigen-binding molecule of claim 3 , wherein the antibody fragment is a Fab, Fab′, scFab, Fv, scFv, or single domain antibody.

5 . The antigen-binding molecule of claim 3 , wherein at least one of amino acid residues from which the bonds between the antigen-binding domains originate is present within a constant region.

6 . The antigen-binding molecule of claim 3 , wherein at least one of amino acid residues from which the bonds between the antigen-binding domains originate is present within a variable region.

7 . The antigen-binding molecule of claim 1 , wherein the first antigen-binding domain and the second antigen-binding domain are linked with each other via two or more bonds.

8 . The antigen-binding molecule of claim 7 , wherein at least one of amino acid residues from which the bonds between the antigen-binding domains originate is present within a hinge region.

9 . The antigen-binding molecule of claim 7 , wherein at least one of amino acid residues from which the bonds between the antigen-binding domains originate is present within the antibody fragment, and at least one of said amino acid residues is present within a hinge region.

10 . The antigen-binding molecule of claim 1 , wherein the antigen-binding domain comprises an Fc region.

11 . The antigen-binding molecule of claim 1 , which has activity of regulating interaction between two antigen molecules.

12 . The antigen-binding molecule of claim 1 , which has resistance to protease cleavage.

13 . A pharmaceutical composition comprising the antigen-binding molecule of claim 1 and a pharmaceutically acceptable carrier.

14 . A method for regulating interaction between two antigen molecules, comprising:
(a) providing an antigen-binding molecule comprising two antigen-binding domains, (b) adding to the antigen-binding molecule at least one bond which links the two antigen-binding domains with each other, and (c) contacting the antigen-binding molecule produced in (b) with the two antigen molecules.

15 . A method for producing an antigen-binding molecule which has activity of regulating interaction between two antigen molecules, comprising:
(a) providing a nucleic acid encoding a polypeptide comprising a first antigen-binding domain and a nucleic acid encoding a polypeptide comprising a second antigen-binding domain, (b) introducing a mutation into the nucleic acids encoding the two antigen-binding domains such that at least one bond linking the two antigen-binding domains is added, (c) introducing the nucleic acids produced in (b) into a host cell, (d) culturing the host cell such that the two polypeptides are expressed, and (e) obtaining an antigen-binding molecule which is a polypeptide comprising the first and second antigen-binding domains, wherein the two antigen-binding domains are linked with each other via one or more bonds.

16 . A nucleic acid or nucleic acids encoding the antigen-binding molecule of claim 1 .

17 . A vector comprising the nucleic acid or nucleic acids of claim 16 .

18 . A host cell comprising the nucleic acid or nucleic acids of claim 16 .

19 . A method of producing an antigen-binding molecule comprising culturing the host cell of claim 18 under conditions suitable for expression of the antigen-binding molecule, and optionally recovering the antigen-binding molecule.

Assignees

• Chugai Pharmaceutical Co Ltd

Inventors

• Shiraiwa Hirotake
• Kawa Tatsuya

Classifications

• C07K16/2818 Primary

  against CD28 or CD152 · CPC title

• C07K16/2809 Primary

  against the T-cell receptor (TcR)-CD3 complex · CPC title

• C07K16/2866

  against receptors for cytokines, lymphokines, interferons · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/31

  multispecific · CPC title